Kombinatsiya CJC-1295/Ipamorelin: Obzor issledovaniy i predposylki

Kombinatsiya CJC-1295 i Ipamorelinma otnositsya k naibolee chasto obsuzhdaemym peptidnym stekam v issledovaniyakh GH. Oba peptida stimuliruyut vysvobozhdenie gormona rosta, no cherez razlichnye retseptornye sistemy. Etot komplementarnyy mekhanizm yavlyaetsya prichinoy, po kotoroy kombinatsiya izuchalas v issledovatelskikh usloviyakh.

V etoy statie obobshchayutsya dostupnye dannye: mekhanizmy deystviya, farmakokineticheskye razlichiya, dannye o sinergii i profili bezopasnosti oboikh peptidov.

CJC-1295/Ipamorelingrowth

Смесь 2-в-1 для гормона роста. Естественная стимуляция ГР через два механизма. Золотой стандарт среди комбинаций для гормона роста.

CJC-1295: Analog GHRH s prodlennym deystviem

CJC-1295 - sinteticheskiy analog gormona, vysvobozhdayushchego gormon rosta (GHRH). On sostoit iz pervykh 29 aminokislot naturalnogo GHRH s chetyrmya aminokislotnymi substitutsiyami, kotorye obespechivayut ustoychivost k degradatsii dipeptidilpeptidazoy-4 (DPP-4).

S DAC i bez DAC

Klyuchevoe prakticheskoe razlichie kasaetsya varianta:

• CJC-1295 s DAC (Drug Affinity Complex): Komponent DAC svyazyvaetsya s albuminom v krovi, udlinyaya period poluraspada do priblizitelno 6-8 dney. Odnokratnaya inektsiya mozhet povyshat urovni GH v techenie neskolkikh dney.
• CJC-1295 bez DAC (takzhe nazyvaemyy Mod GRF 1-29): Period poluraspada okolo 30 minut. Trebuet mnogokratnogo ezhednvnogo dozirovaniya, no proizvdit bolee pulsatilnyy pattern vysvobozhdeniya.

Klinicheskie dannye

Teichman et al. (2006) opublikovali klyuchevoe klinicheskoe issledovanie CJC-1295 s DAC v Journal of Clinical Endocrinology & Metabolism. V etom randomizirovannom, platsebo-kontroliruemom, dvoynom slepom issledovanii u zdorovykh vzroslykh (21-61 god) odnokratnaya podkozhnaya inektsiya proizvela:

• Dozozavisimye povysheniya GH v 2-10 raz v techenie 6 dney ili dolee
• Povysheniya IGF-1 v 1,5-3 raza v techenie 9-11 dney
• Otsenochnyy period poluraspada: 5,8-8,1 dney
• Svidetelstva kumulyativnogo effekta pri povtornom dozirovanii

Avtory opisali vvedenie kak bezopasnoe i khorosho perenosimoe, osobenno pri dozakh 30 ili 60 mkg/kg. Soobshchennye pobochnye effekty byli legkimi reaktsiyami v meste inektsii.

Ipamorelin: Selektivnyy agonist retseptora grelina

Ipamorelin - pentapeptid, deystvuyushchiy na retseptor grelina (GHS-R1a) somatotropnykh kletok gipofiza. On prinadlezhit k klassu peptidov, vysvobozhdayushchikh gormon rosta (GHRP), no otlichaetsya ot bolee starykh predstaviteley znachitelno bolee selektivnym profilem.

Selektivnost kak otlichitelnaya kharakteristika

Raun et al. (1998) opisali Ipamorelin v European Journal of Endocrinology kak "pervyy selektivnyy sekretagog gormona rosta". Klyuchevoe nablyudenie:

• Ipamorelin vysvobodil GH bez znachitelnogo povysheniya AKTH ili kortizola vyshe kontrolnykh urovney GHRH
• Dazhe pri dozakh, prevyshayushchikh v 200 raz ED50 dlya vysvobozhdeniya GH, urovni kortizola ostavalsi stabilnymi
• Otsutstvie znachitelnogo vliyaniya na FSH, LH, prolaktin ili TSH

Dlya sravneniya: GHRP-6 i GHRP-2 proizvodyat izmerimye povysheniya AKTH i kortizola pri ekvivalentnykh dozakh, stimuliruyushchikh GH. Eti pobochnye effekty ogranichivayut ikh ispolzovanie v opredelennykh issledovatelskikh kontekstakh.

Sinergiya: GHRH + GHRP

Kombinatsiya analoga GHRH s GHRP ne yavlyaetsya novoy kontseptsiey. Bowers et al. opisali eshche v 1991 godu v Endocrinology, chto GHRP stimuliruet vysvobozhdenie GH cherez nezavisimyy, komplementarnyy mekhanizm - otdelno ot retseptora GHRH i nezavisimo ot opiatnykh retseptorov.

Dva otdelnykh signalnykh puti

Sinergisticheskiy effekt voznikaet pri odnovremennoy aktivatsii dvukh razlichnykh retseptornykh sistem:

1. Retseptor GHRH (aktivirovannyy CJC-1295): Stimuliruet signalnuyu kaskadu cAMP v somatotropnykh kletkakh
2. GHS-R1a (aktivirovannyy Ipamorelinmom): Stimuliruet kaskadu fosfolipazy C i vnutrikletochnoe vysvobozhdenie kaltsiya

Eti otdelnye vnutrikletochnye signalnye puti skhodyatsya pri sekretsii GH, proizvdya vmeste bolee silnyy otvet, chem kazhdyy put v otdelnosti.

Kolichestvennye dannye

Veldhuis et al. (2009) sistematicheski issledovali determinanty sinergii GHRH-GHRP v American Journal of Physiology. Osnovnye rezultaty:

• Sovmestnoe vvedenie proizvelo v 2-4 raza bolshuyu AUC GH (ploshchad pod krivoy) po sravneniyu s kazhdym soedineniyem v otdelnosti
• Effekt byl ot additivnogo do sinergisticheskogo v zavisimosti ot vremeni
• Povysheniya IGF-1 byli priblizitelno na 20-30% vyshe, chem pri odnorazovom vvedenii

Eti dannye otnosyatsya k obshchey kombinatsii GHRH+GHRP. Spetsificheskie klinicheskie issledovaniya tochnoy kombinatsii CJC-1295 s Ipamorelinmom ogranicheny. Perenosimost vytekayet iz obshchey retseptornoy farmakologii.

DAC ili bez DAC: Chto vazhno dlya issledovaniy?

Vybor varianta CJC-1295 imeet pryamye posledstviya dlya dizayna issledovaniya:

Parametr	CJC-1295 s DAC	CJC-1295 bez DAC (Mod GRF 1-29)
Period poluraspada	6-8 dney	ok. 30 minut
Pattern vysvobozhdeniya GH	Postoyannye povyshennyy bazalnyy uroven	Pulsatilnyy
Chastota dozirovaniya	1-2 raza v nedelyu	2-3 raza v den
Fiziologicheskoe skhodstvo	Menee fiziologichnyy	Blizhe k estestvennomu patternu

Variant DAC proizvodit ustoychivoe povyshenie GH, kotoroe ne sootvetstvuet estestvennomu pulsatilnomu patternu. Dlya issledovatelskikh voprosov, gde fiziologicheskaya pulsatilnost vazhna, chasto predpochitaetsya variant bez DAC.

Odnako issledovanie Ionescu & Bhatt (2006) pokazalo, chto pulsatilnaya sekretsiya GH sokhranmayetsya dazhe pri nepreryvnoy stimulyatsii CJC-1295 DAC - endogennaya somatostatinovaya regulyatsiya, po-vidimomu, ostaetsya funktsionalnoy.

Profil bezopasnosti

CJC-1295

Dannye Teichmana et al. (2006) ne pokazali sereznykh nezhelatelnykh yavleniy v issledovannykh diapazonakh doz (30-60 mkg/kg). Soobshchennye legkie pobochnye effekty vklyuchali:

• Reaktsii v meste inektsii (pokrasnenie, otek)
• Prekhodyashchie prilivy
• Legkaya retentsiya zhidkosti

Ipamorelin

Ipamorelin opisyvaetsya v literature kak khorosho perenosimyy. Naibolee chasto soobshchaemye legkie effekty:

• Golovnye boli
• Prekhodyashchaya ustalost
• Legkaya toshnota

Otsutstvie znachitelnykh povysheniy kortizola i prolaktina predstavlyayet preimushchestvo bezopasnosti pered drugimi GHRP.

Rezyume issledovaniy

Kombinatsiya CJC-1295/Ipamorelin ispolzuet komplementarnuyu retseptornuyu farmakologiyu signalnykh putey GHRH i GHRP. Dannye podderzhivayut sleduyushchie klyuchevye punkty:

• CJC-1295 prodlevayet aktivatsiyu retseptora GHRH i dozozavisimo povysil GH i IGF-1 v klinicheskikh issledovaniyakh (Teichman et al., 2006)
• Ipamorelin - naibolee selektivnyy izvestnyy GHRP s minimalnym vliyaniem na kortizol i prolaktin (Raun et al., 1998)
• Kombinatsii GHRH+GHRP proizvodyat sinergisticheskie otvety GH s v 2-4 raza bolshey AUC, chem otdelnye soedineniya (Veldhuis et al., 2009)
• Oba peptida prodemonstrirovali blagopriyatnyy profil bezopasnosti v kratkosrochnykh issledovaniyakh

Issledovaniya etoy kombinatsii ostayutsya aktivnymi, no dolgosrochnye dannye i krupnye randomizirovannye issledovaniya otsutstvuyut. Dlya tekushchego sostoyaniya znaniy tsitiruemye publikatsii obespechivayut solidnuyu osnovu.

Chasto zadavaemye voprosy

Zakazat CJC-1295/Ipamorelin

CJC-1295/Ipamorelingrowth

Смесь 2-в-1 для гормона роста. Естественная стимуляция ГР через два механизма. Золотой стандарт среди комбинаций для гормона роста.

Ssylki

1. Teichman SL et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab, 91(3), 799-805.
2. Raun K et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol, 139(5), 552-561.
3. Bowers CY et al. (1991). On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology, 128(4), 2027-2035.
4. Veldhuis JD et al. (2009). Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. Am J Physiol Endocrinol Metab, 296(5), E1085-E1092.
5. Ionescu M, Bhatt DL (2006). Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab, 91(12), 4792-4797.